These findings suggest that polymorphisms within the enhancer region upstream of IRF5 are involved in SLE pathogenesis by affecting the expression of IRF5 and inflammatory cytokines in myeloid cells. The gene discussed is IRF5; the disease is systemic lupus erythematosus.